Cencora, Inc. COR
354.00 USD +13.50 (+3.96%)
At closeNov 4, 2026, 5:15 PM EST
355.00 +1.00 +0.28%
After hours · Nov 4, 5:15 PM ET
336.72 Day range 355.64
244.82 52-week range 377.54
- YTD
- +4.81%
- 1 year
- +2.75%
News
zacks.com Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand COR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.
seekingalpha.com Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript
zacks.com Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Cencora Q4 2026 Earnings Call Transcript Cencora (NYSE:COR) reported fourth-quarter financial results on Wednesday. The transcript from the company’s fourth-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates Cencora (COR) came out with quarterly earnings of $4.66 per share, beating the Zacks Consensus Estimate of $4.56 per share. This compares to earnings of $3.84 per share a year ago.
benzinga.com Cencora Increases Quarterly Dividend From $0.60 To $0.66 Per Share; Announces Corporate Realignment To Separate Out Specialty Solutions On November 3, 2026, the Company declared a quarterly dividend of $0.66 per common share, a 10 percent increase in its quarterly dividend rate from $0.60 per common share. The quarterly dividend of…
benzinga.com Cencora Sees FY2027 Adj EPS $19.40-$19.75 vs $19.70 Est; Sees Sales $347.519B-$354.267B vs $352.380B Est Cencora (NYSE:COR) is looking for FY2027 Adj EPS of $19.40-$19.75 vs $19.70 analyst estimate. sees sales of $347.519 billion-$354.267 billion vs $352.380 billion analyst estimate.
businesswire.com Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion.…
businesswire.com Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. “Over the last two…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
zacks.com Why Cencora (COR) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Lumentum Holdings Inc. (Nasdaq – LITE), Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC) BALA CYNWYD, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
seekingalpha.com Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November Emerson is set to extend its dividend growth streak to 70 years, with a predicted 6.3–8.1% increase driven by a business transformation. EMR's shift to higher-margin Intelligent Devices and Software…- benzinga.com Morgan Stanley Maintains Overweight on Cencora, Raises Price Target to $377 Morgan Stanley analyst Erin Wright maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $346 to $377.
zacks.com Cencora Gears Up to Report Q4 Results: How to Play the Stock? COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.
zacks.com Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the…
zacks.com Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network COR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ) BALA CYNWYD, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
benzinga.com Baird Maintains Outperform on Cencora, Raises Price Target to $375 Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $373 to $375.
globenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD) BALA CYNWYD, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky…
benzinga.com Here’s How Much You Would Have Made Owning Cencora Stock In The Last 5 Years Cencora (NYSE:COR) has outperformed the market over the past 5 years by 11.54% on an annualized basis producing an average annual return of 22.6%. Currently, Cencora has a market capitalization of…
reuters.com Cencora to acquire American Oncology Network in $2.4 billion deal Cencora to acquire American Oncology Network in $2.4 billion deal
benzinga.com Cencora Agrees To Acquire Remaining Stake In American Oncology Network For $2.4B Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. ("AON") (OTCQX:AONC), a physician-led network of more than 350 oncology…
businesswire.com Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC),…
benzinga.com Argus Research Maintains Buy on Cencora, Raises Price Target to $380 Argus Research analyst David Toung maintains Cencora (NYSE:COR) with a Buy and raises the price target from $340 to $380.
defenseworld.net IFP Advisors Inc Purchases 14,078 Shares of Cencora, Inc. $COR IFP Advisors Inc raised its holdings in Cencora, Inc. (NYSE: COR) by 227.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund…
defenseworld.net Cencora, Inc. $COR Stake Increased by Frank Rimerman Advisors LLC Frank Rimerman Advisors LLC grew its holdings in Cencora, Inc. (NYSE: COR) by 235.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional…
defenseworld.net Cencora (NYSE:COR) and Option Care Health (NASDAQ:OPCH) Financial Contrast Cencora (NYSE: COR - Get Free Report) and Option Care Health (NASDAQ: OPCH - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on…
seekingalpha.com AI Disruption May Benefit Cencora More Than Hims & Hers Cencora (COR) stands to benefit from AI-driven increases in prescription volumes as regulatory pilots expand automated prescribing. COR's operational leverage and AI-enabled efficiency improvements…
defenseworld.net 23,420 Cencora, Inc. $COR Shares Bought by NorthCrest Asset Manangement LLC NorthCrest Asset Manangement LLC increased its holdings in Cencora, Inc. (NYSE: COR) by 1,255.1% during the third quarter, according to the company in its most recent disclosure with the Securities…
defenseworld.net Hims & Hers Health (NYSE:HIMS) vs. Cencora (NYSE:COR) Head to Head Review Cencora (NYSE: COR - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies…
benzinga.com If You Invested $1000 In Cencora Stock 10 Years Ago, You Would Have This Much Today Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.46% on an annualized basis producing an average annual return of 20.2%. Currently, Cencora has a market capitalization of…
benzinga.com Cencora Q3 2026 Earnings Call Transcript Cencora (NYSE:COR) held its third-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time…- benzinga.com Leerink Partners Maintains Outperform on Cencora, Raises Price Target to $388 Leerink Partners analyst Michael Cherny maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $380 to $388.
seekingalpha.com Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow Cencora gets its prior buy rating reaffirmed again. Despite some market underperformance, specific business and macro fundamentals remain supportive. An investment-grade rating, positive operating…- benzinga.com $100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.44% on an annualized basis producing an average annual return of 20.45%. Currently, Cencora has a market capitalization of…
- benzinga.com $1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.79% on an annualized basis producing an average annual return of 20.35%. Currently, Cencora has a market capitalization of…
benzinga.com RBC Capital Reiterates Sector Perform on Cencora, Maintains $330 Price Target RBC Capital analyst Ryan Halsted reiterates Cencora (NYSE:COR) with a Sector Perform and maintains $330 price target.
benzinga.com Walmart Agrees to $50 Million Settlement With DOJ Over Alleged Opioid Prescription Violations, Calls Payout ‘Immaterial’ Walmart agreed to pay $50 million to settle a DOJ lawsuit alleging its pharmacies unlawfully filled opioid prescriptions.- benzinga.com $100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.61% on an annualized basis producing an average annual return of 19.99%. Currently, Cencora has a market capitalization of…
benzinga.com RBC Capital Initiates Coverage On Cencora with Sector Perform Rating, Announces Price Target of $330 RBC Capital analyst Ryan Halsted initiates coverage on Cencora (NYSE:COR) with a Sector Perform rating and announces Price Target of $330.- benzinga.com If You Invested $1000 In Cencora Stock 10 Years Ago, You Would Have This Much Today Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.29% on an annualized basis producing an average annual return of 19.83%. Currently, Cencora has a market capitalization of…
- benzinga.com Cencora Says Certain Walgreens Volume Moves Outside Cencora From July 1, 2026; Reaffirms FY26 Adj Diluted EPS Guidance Range Of $17.75-$17.95; Says Prime Vendor Agreement With Walgreens Remains Unchanged Beginning July 1, 2026, certain Walgreens volume that was being serviced by Cencora, Inc. (the "Company" or "Cencora") separate from the prime vendor agreement began moving outside the Company. The…
- benzinga.com Wells Fargo Maintains Overweight on Cencora, Raises Price Target to $395 Wells Fargo analyst Stephen Baxter maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $331 to $395.
- benzinga.com Morgan Stanley Maintains Overweight on Cencora, Raises Price Target to $346 Morgan Stanley analyst Erin Wright maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $342 to $346.
- benzinga.com JP Morgan Maintains Overweight on Cencora, Raises Price Target to $390 JP Morgan analyst Lisa Gill maintains Cencora (NYSE:COR) with a Overweight and raises the price target from $382 to $390.
benzinga.com Terrible Jobs Report Sparks Rally In AI and Tech: 10 Stocks Leading Friday's Surge Weak U.S. jobs data boosts hopes for a Fed pause, sending AI chip stocks and other high-beta tech names sharply higher. Here are 10 stocks to watch.- benzinga.com Evercore ISI Group Maintains Outperform on Cencora, Raises Price Target to $350 Evercore ISI Group analyst John Belton maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $330 to $350.
benzinga.com Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins Cencora beats third-quarter earnings and revenue estimates, raised fiscal 2026 EPS guidance and maintains its annual sales forecast.